EYLEA® (afibercept) injection, for intravitreal use
Initial U.S. Approval: 2011

INDICATIONS AND USAGE
EYLEA HD is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with:
- Neovascular (Wet) Age-Related Macular Degeneration (nAMD) (1.1)
- Diabetic Macular Edema (DME) (1.2)
- Diabetic Retinopathy (DR) (1.3)

DOSAGE AND ADMINISTRATION

2.1 Important Injection Instructions

2.2 Neovascular (Wet) Age-Related Macular Degeneration (nAMD)
- The recommended dose for EYLEA HD is 8 mg (0.07 mL of 114.3 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days +/- 7 days) for the first three doses, followed by 8 mg (0.07 mL of 114.3 mg/mL solution) via intravitreal injection once every 8 to 16 weeks, +/- 1 week. (2.2)

2.3 Diabetic Macular Edema (DME)
- The recommended dose for EYLEA HD is 8 mg (0.07 mL of 114.3 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days +/- 7 days) for the first three doses, followed by 8 mg (0.07 mL of 114.3 mg/mL solution) via intravitreal injection once every 8 to 16 weeks, +/- 1 week. (2.3)

2.4 Diabetic Retinopathy (DR)
- The recommended dose for EYLEA HD is 8 mg (0.07 mL of 114.3 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days +/- 7 days) for the first three doses, followed by 8 mg (0.07 mL of 114.3 mg/mL solution) via intravitreal injection once every 8 to 16 weeks, +/- 1 week. (2.4)

2.5 Preparation for Administration

2.6 Injection Procedure

DOSAGE FORMS AND STRENGTHS

- Injection: 8 mg (0.07 mL of 114.3 mg/mL solution) in a single-dose vial (3)

CONTRAINDICATIONS

- Ocular or periorcular infection (4.1)
- Active intraocular inflammation (4.2)
- Hypersensitivity (4.3)

WARNINGs AND PRECAUTIONs

The most common adverse reactions (≥3%) reported in patients treated with EYLEA HD were cataract, conjunctival hemorrhage, intraocular pressure increased, ocular discomfort/eye pain/eye irritation, vision blurred, vitreous floaters, vitreous detachment, corneal epithelium defect, and retinal hemorrhage. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Regeneron at 1-855-395-3248 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 08/2023

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE
   1.1 Neovascular (Wet) Age-Related Macular Degeneration (nAMD)
   1.2 Diabetic Macular Edema (DME)
   1.3 Diabetic Retinopathy (DR)

2 DOSAGE AND ADMINISTRATION
   2.1 Important Injection Instructions
   2.2 Neovascular (Wet) Age-Related Macular Degeneration (nAMD)
   2.3 Diabetic Macular Edema (DME)
   2.4 Diabetic Retinopathy (DR)
   2.5 Preparation for Administration
   2.6 Injection Procedure

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS
   4.1 Ocular or Periorcular Infections
   4.2 Active Intraocular Inflammation
   4.3 Hypersensitivity

5 WARNINGS AND PRECAUTIONS
   5.1 Endophthalmitis and Retinal Detachments
   5.2 Increase in Intraocular Pressure
   5.3 Thromboembolic Events

6 ADVERSE REACTIONS
   6.1 Clinical Trials Experience

8 USE IN SPECIFIC POPULATIONS
   8.1 Pregnancy
   8.2 Lactation
   8.3 Females and Males of Reproductive Potential
   8.4 Pediatric Use
   8.5 Geriatric Use

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY
   12.1 Mechanism of Action
   12.2 Pharmacodynamics
   12.3 Pharmacokinetics
   12.6 Immunogenicity

13 NONCLINICAL TOXICOLOGY
   13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
   13.2 Animal Toxicology and/or Pharmacology

14 CLINICAL STUDIES
   14.1 Neovascular (Wet) Age-Related Macular Degeneration (nAMD)
   14.2 Diabetic Macular Edema (DME)
   14.3 Diabetic Retinopathy (DR)

16 HOW SUPPLIED/STORAGE AND HANDLING
   16.1 How Supplied
   16.2 Storage and Handling

17 PATIENT COUNSELING INFORMATION
   * Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

EYLEA HD is indicated for the treatment of:
- Neovascular (Wet) Age-Related Macular Degeneration (nAMD) (1.1)
- Diabetic Macular Edema (DME) (1.2)
- Diabetic Retinopathy (DR) (1.3)

2 DOSAGE AND ADMINISTRATION

2.1 Important Injection Instructions

For ophthalmic intravitreal injection, EYLEA HD must only be administered by a qualified physician.

A 5-micron sterile filter needle (18-gauge x ½-inch), a 1-mL Luer lock syringe and a 30-gauge x ½-inch sterile injection needle are needed.

EYLEA HD is available packaged as follows:
- Vial Only
- Vial Kit with Injection Components (filter needle, syringe, injection needle) [see How Supplied/Storage and Handling (16)].

2.2 Neovascular (Wet) Age-Related Macular Degeneration (nAMD)

The recommended dose for EYLEA HD is 8 mg (0.07 mL of 114.3 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days +/- 7 days) for the first three doses, followed by 8 mg (0.07 mL of 114.3 mg/mL solution) via intravitreal injection once every 8 to 16 weeks, +/- 1 week.

2.3 Diabetic Macular Edema (DME)

The recommended dose for EYLEA HD is 8 mg (0.07 mL of 114.3 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days +/- 7 days) for the first three doses, followed by 8 mg (0.07 mL of 114.3 mg/mL solution) via intravitreal injection once every 8 to 16 weeks, +/- 1 week.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Lactation

8.3 Females and Males of Reproductive Potential

8.4 Pediatric Use

8.5 Geriatric Use

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

12.6 Immunogenicity

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

13.2 Animal Toxicology and/or Pharmacology

14 CLINICAL STUDIES

14.1 Neovascular (Wet) Age-Related Macular Degeneration (nAMD)

14.2 Diabetic Macular Edema (DME)

14.3 Diabetic Retinopathy (DR)

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

16.2 Storage and Handling

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.
2.4 Diabetic Retinopathy (DR)

The recommended dose for EYLEA HD is 8 mg (0.07 mL of 114.3 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days +/- 7 days) for the first three doses, followed by 8 mg (0.07 mL of 114.3 mg/mL solution) via intravitreal injection once every 8 to 12 weeks, +/- 1 week.

2.5 Preparation for Administration

The EYLEA HD glass vial is for one-time use in one eye only. Discard unused portion. EYLEA HD does not contain an anti-microbial preservative. Extraction of multiple doses from a single vial may increase the risk of contamination and subsequent infection.

Do not use if the package or its components are expired, damaged, or have been tampered with.

Check the label on the vial to make sure you have the correct aflibercept strength.

Prepare for intravitreal injection with the following medical devices for single use.

- a 5-micron sterile filter needle (18-gauge × 1½-inch)
- a 1-mL sterile Luer lock syringe (with marking to measure 0.07 mL)
- a sterile injection needle (30-gauge × ½-inch)

1. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use the vial if particulates, cloudiness, or discoloration are visible.

2. Remove the protective plastic cap from the vial (see Figure 1).

3. Clean the top of the vial with an alcohol wipe (see Figure 2).

4. Use aseptic technique to carry out steps 4 – 11. Remove the 18-gauge × 1½-inch, 5-micron, filter needle and the 1-mL syringe from their packaging. Attach the filter needle to the syringe by twisting it onto the Luer lock syringe tip (see Figure 3).

5. Push the filter needle into the center of the vial stopper until the needle is completely inserted into the vial and the tip touches the bottom or bottom edge of the vial.

6. Withdraw all of the EYLEA HD vial contents into the syringe, keeping the vial in an upright position, slightly inclined to ease complete withdrawal. To deter the introduction of air, ensure the bevel of the filter needle is submerged into the liquid. Continue to tilt the vial during withdrawal keeping the bevel of the filter needle submerged in the liquid (see Figure 4a and Figure 4b).

7. Ensure that the plunger rod is drawn sufficiently back when emptying the vial in order to completely empty the filter needle.

8. Remove the filter needle from the syringe and properly dispose of the filter needle. **Note:** Filter needle is not to be used for intravitreal injection.

9. Remove the 30-gauge × ½-inch injection needle from its packaging and attach the injection needle to the syringe by firmly twisting the injection needle onto the Luer lock syringe tip (see Figure 5).

10. Holding the syringe with the needle pointing up, check the syringe for bubbles. If there are bubbles, gently tap the syringe with your finger until the bubbles rise to the top (see Figure 6).

11. To eliminate all of the bubbles and to expel excess drug, SLOWLY depress the plunger so that the plunger tip aligns with the line that marks 0.07 mL on the syringe (see Figure 7a and Figure 7b).

2.6 Injection Procedure

The intravitreal injection procedure should be carried out under controlled aseptic conditions, which include surgical hand disinfection and the use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a topical broad-spectrum microbicide should be given prior to the injection.

Immediately following the intravitreal injection, patients should be monitored for elevation in intraocular pressure. Appropriate monitoring may consist of a check for perfusion of the optic nerve head or tonometry. If required, a sterile paracentesis needle should be available.
Following intravitreal injection, patients and/or caregivers should be instructed to report any signs and/or symptoms suggestive of endophthalmitis or retinal detachment (e.g., eye pain, redness of the eye, photophobia, blurring of vision) without delay [see Patient Counseling Information (17)].

Each vial should only be used for the treatment of a single eye. If the contralateral eye requires treatment, a new vial should be used and the sterile field (including a new syringe, gloves, drapes, eyelid speculum, filter and injection needles) should be changed before EYLEA HD is administered to the other eye.

After injection, discard any unused product or waste material in accordance with local regulations.

3 DOSAGE FORMS AND STRENGTHS

EYLEA HD is a clear to slightly opalescent, colorless to pale yellow solution available as:

- Injection: 8 mg (0.07 mL of a 114.3 mg/mL solution) in a single-dose glass vial

4 CONTRAINDICATIONS

4.1 Ocular or Periocular Infections

EYLEA HD is contraindicated in patients with ocular or periocular infections.

4.2 Active Intraocular Inflammation

EYLEA HD is contraindicated in patients with active intraocular inflammation.

4.3 Hypersensitivity

EYLEA HD is contraindicated in patients with known hypersensitivity to aflibercept or any of the excipients in EYLEA HD. Hypersensitivity reactions may manifest as rash, pruritus, urticaria, severe anaphylactic/anaphylactoid reactions, or severe intraocular inflammation.

5 WARNINGS AND PRECAUTIONS

5.1 Endophthalmitis and Retinal Detachments

Intravitreal injections including those with aflibercept have been associated with endophthalmitis and retinal detachments [see Adverse Reactions (6.1)]. Proper aseptic injection technique must always be used when administering EYLEA HD. Patients and/or caregivers should be instructed to report any signs and/or symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately [see Dosage and Administration (2.6) and Patient Counseling Information (17)].

5.2 Increase in Intraocular Pressure

Acute increases in intraocular pressure have been seen within 60 minutes of intravitreal injection, including with EYLEA HD [see Adverse Reactions (6.1)]. Sustained increases in intraocular pressure have also been reported after repeated intravitreal dosing with vascular endothelial growth factor (VEGF) inhibitors. Intravitreal pressure and the perfusion of the optic nerve head should be monitored and managed appropriately [see Dosage and Administration (2.6)].

5.3 Thromboembolic Events

There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including EYLEA HD. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause). The incidence of reported thromboembolic events in the wet AMD study (PULSAR) from baseline through week 48 was 3.1% (15 out of 491) in the combined group of patients treated with EYLEA HD compared with 0.4% (3 out of 673) in the combined group of patients treated with EYLEA 2 mg. The incidence of reported thromboembolic events in the DME study (PHOTON) from baseline to week 48 was 3.3% (15 out of 491) in the combined group of patients treated with EYLEA HD compared with 3.6% (6 out of 167) in patients treated with EYLEA 2 mg.

6 ADVERSE REACTIONS

The following potentially serious adverse reactions are described elsewhere in the labeling:

- Hypersensitivity [see Contraindications (4.3)]
- Endophthalmitis and retinal detachments [see Warnings and Precautions (5.1)]
- Increase in intraocular pressure [see Warnings and Precautions (5.2)]
- Thromboembolic events [see Warnings and Precautions (5.3)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in other clinical trials of the same or another drug and may not reflect the rates observed in practice.

A total of 1164 patients were treated with EYLEA HD and 593 patients were treated with EYLEA 2 mg in two clinical studies. The most common adverse reactions reported in ≥3% of patients treated with EYLEA HD were cataract, conjunctival hemorrhage, intraocular pressure increased, ocular discomfort/eye pain/eye irritation, vision blurred, vitreous floaters, vitreous detachment, corneal epithelial defect, and retinal hemorrhage. The data described below reflect exposure to EYLEA HD or EYLEA 2 mg in controlled clinical studies (PULSAR and PHOTON), each for 48 weeks [see Clinical Studies (14.1, 14.2)].

Adverse drug reactions (ADRs) reported in <1% of participants treated with EYLEA HD were ocular hyperemia (includes adverse events of conjunctival hyperemia, conjunctival irritation, ocular hyperemia), lacrimation increased, eyelid edema, hypersensitivity (includes adverse events of rash, urticaria, pruritus), retinal tear and injection site hemorrhage.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Adequate and well-controlled studies with EYLEA HD have not been conducted in pregnant women. Aflibercept produced adverse embryofetal effects in rabbits, including external, visceral, and skeletal malformations. A fetal No Observed Adverse Effect Level (NOAEL) was not identified. At the lowest dose shown to produce adverse embryofetal effects, systemic exposure (based on AUC for free aflibercept) was approximately 0.9-fold of the population pharmacokinetic estimated exposure in humans after an intravitreal dose of 8 mg (see Data).

Animal reproduction studies are not always predictive of human response, and it is not known whether EYLEA HD can cause fetal harm when administered to a pregnant woman. Based on the anti-VEGF mechanism of action for aflibercept [see Clinical Pharmacology (12.7)], treatment with EYLEA HD may pose a risk to human embryofetal development. EYLEA HD should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data

Animal Data

In two embryofetal development studies, aflibercept produced adverse embryofetal effects when administered every three days during organogenesis to pregnant rabbits at intravenous doses ≥3 mg per kg, or every six days during organogenesis at subcutaneous doses ≥0.1 mg per kg.

Adverse embryofetal effects included increased incidences of postimplantation loss and fetal malformations, including anasarca, umbilical hernia, diaphragmatic hernia, gastrochisis, cleft palate, ectrodactyly, intestinal atresia, spina bifida, encephalomalacicencele, heart and major vessel defects, and skeletal malformations (fused vertebrae, sternebrae, ribs; supernumerary vertebral arches and ribs; and incomplete ossilation). The maternal No Observed Adverse Effect Level (NOAEL) in these studies was 3 mg per kg.

Aflibercept produced fetal malformations at all doses assessed in rabbits and the fetal
Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are
not contain an anti-microbial preservative.

in a total molecular weight of 115 kDa. Aflibercept is produced in recombinant Chinese
hamster ovary (CHO) cells.

EYLEA HD (aflibercept) injection is a sterile, clear to slightly opalescent, and colorless to
pale yellow solution. EYLEA HD is supplied as a sterile, aqueous solution for intravitreal
administration of aflibercept intravitreally was 3.5 weeks.

Absorption/Distribution
As no relevant differences in pharmacokinetics between the nAMD and DME populations
were observed based on a population pharmacokinetic analysis of the data, population
pharmacokinetic estimated parameters are presented for the two populations combined.
Following unilateral intravitreal administration of 8 mg aflibercept, the mean (SD) Cmax of
free aflibercept in plasma was 0.30 (0.27) mg/L, and the median time to maximal
concentration in plasma was 2.9 days. The accumulation of free aflibercept in plasma
following three initial monthly intravitreal doses was minimal (mean accumulation ratio
1:2); subsequently, no further accumulation was observed.

The volume of distribution of free aflibercept following intravenous (I.V.) administration
of aflibercept is approximately 7 L.

Metabolism/Elimination
Aflibercept is a therapeutic protein and no drug metabolism studies have been conducted.
Aflibercept is expected to undergo elimination through both target-mediated disposition via
binding to free endogenous VEGF and metabolism via proteolysis. The median time to
reach non-quantifiable concentrations of free aflibercept in plasma for 8 mg administered
intravitreally was 3.5 weeks.

Specific Populations
Renal and Hepatic Impairment
Population pharmacokinetic analysis revealed that systemic exposures to aflibercept in
patients with mild to severe renal impairment (eGFR 15 to < 90 mL/min, estimated using
the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation for eGFR)
were similar to those with normal renal function. Mild hepatic impairment had no influence
on systemic exposures to aflibercept compared to patients with normal hepatic function.
No data for patients with moderate and severe hepatic impairment are available. No dose
adjustment based on renal or hepatic impairment status is needed.

Other
No dosage adjustment is required for any of the populations that have been studied (e.g.,
age and race).

12.8 Immunogenicity
The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and
specificity of the assay. Differences in assay methods preclude meaningful comparisons
of results between trials. The incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies for other products.

During the 48-week treatment with aflibercept administrated IVT, the incidence of
anti-aflibercept antibody formation in the 8 mg treatment groups was 2.7% (25/937 participants with nAMD [PULSAR] or DME [PHOTON]).

13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
No studies have been conducted on the mutagenic or carcinogenic potential of aflibercept.
Effects on male and female fertility were assessed as part of a 6-month study in monkeys
with intravitreal administration of aflibercept at weekly doses ranging from 3 to 30 mg per
kg. Absent or irregular menses associated with alterations in female reproductive hormone
levels and changes in sperm morphology and motility were observed at all dose levels.
In addition, females showed decreased ovarian and uterine weight accompanied by
compromised luteal development and reduction of maturing follicles. These changes
were correlated with uterine and vaginal atrophy. All changes were reversible within 20 weeks
and cessation of treatment. A No Observed Adverse Effect Level (NOAEL) was not identified.
Intravenous administration of the lowest dose of aflibercept administered in monkeys (3 mg per
kg) resulted in systemic exposure (AUC) for free aflibercept that was 91 times higher than the population pharmacokinetic estimated systemic exposure in humans after an intravitreal dose of 8 mg.

13.2 Animal Toxicology and/or Pharmacology
Erosions and ulcerations of the respiratory epithelium in nasal turbinates of monkeys
infected intravitreally were observed at intravitreal doses of 2, 4 or 7 mg per
eye. At the NOAEL of 0.5 mg per eye in monkeys, the systemic exposure (AUC) for
free aflibercept was approximately 3 times higher than the population pharmacokinetic
estimated exposure observed in humans after an intravitreal dose of 8 mg.

14 CLINICAL STUDIES
14.1 Neovascular (Wet) Age-Related Macular Degeneration (nAMD)
The safety and efficacy of EYLEA HD were assessed in a randomized, multi-center,
combined-treatment, active-controlled study (PULSAR) in treatment-naive patients with nAMD.
A total of 1099 patients were treated and analyzed for efficacy (673 with EYLEA HD). Patients
were randomly assigned in a 1:1:1 ratio to 1 of 3 treatment groups: 1) EYLEA HD administered
every 12 weeks following 3 initial monthly doses (HDq12); 2) EYLEA HD administered every 16 weeks following 3 initial monthly doses (HDq16); 3) EYLEA 2 mg administered every 8 weeks (2q8) following 3 initial monthly doses. In the
EYLEA HD groups, patients could be treated as frequently as every 8 weeks based on
protocol-defined visual and anatomic criteria, starting at week 16. Patients ranged from 50
to 96 years of age with a mean of 74.5 years. At baseline, mean visual acuity was
approximately 60 letters (range: 24 to 78 letters).

The primary efficacy endpoint was the change from baseline in BCVA at week 48 as
measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score.
Both HDq12 and HDq16 treatments were shown to be non-inferior and clinically equivalent
to 2q8 treatment with respect to the change in BCVA score at week 48 using the
pre-specified non-inferiority margin of 4 letters. In patients completing week 48, the mean
number of injections administered were 5.2 in the HDq16 group (n=316), 6.1 in the HDq12
group (n=316) and 6.9 in the EYLEA q8 group (n=309). Detailed results from the analysis of
the PULSAR study are shown in Table 2 and Figure 8 below.
Efficacy results in all subgroups (e.g., age, gender, geographic region, ethnicity, race, baseline BCVA and lesion type) were consistent with those in the overall population.

### Table 2: Efficacy Outcomes (Full Analysis Set) in PULSAR Study

<table>
<thead>
<tr>
<th>Efficacy Outcomes</th>
<th>EYLEA HDq12</th>
<th>EYLEA HDq16</th>
<th>EYLEA 2q8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Analysis Set</td>
<td>N=335</td>
<td>N=338</td>
<td>N=336</td>
</tr>
<tr>
<td>Mean change in BCVA as measured by ETDRS letter score from baseline (SD) at week 48[^c]</td>
<td>6.7 (12.6)</td>
<td>6.2 (11.7)</td>
<td>7.6 (12.2)</td>
</tr>
<tr>
<td>LS mean (SE) change from baseline[^b]</td>
<td>6.1 (0.8)</td>
<td>5.9 (0.7)</td>
<td>7.0 (0.7)</td>
</tr>
<tr>
<td>Difference in LS mean (95% CI)</td>
<td>-1.0 (-2.9, 0.9)</td>
<td>-1.1 (-3.0, 0.7)</td>
<td></td>
</tr>
</tbody>
</table>

BCVA = Best Corrected Visual Acuity; ETDRS = Early Treatment Diabetic Retinopathy Study; SD = Standard Deviation; LS = Least Square; SE = Standard Error; CI = Confidence Interval; MMRM = Mixed Model for Repeated Measurements.

[^a]: Full Analysis Set (FAS) includes all randomized patients who received at least 1 dose of study medication.
[^b]: Observed values at week 48: n=299 for HDq12; n=156 for HDq16; n=155 for 2q8.
[^c]: Estimate based on the MMRM model, was computed for the differences of HDq12 minus 2q8 and HDq16 minus 2q8, respectively, with two-sided 95% CIs.

Figure 8: Mean Change from Baseline in BCVA as measured by ETDRS Letter Score by Visits through Week 48 (Observed Cases)

### 14.2 Diabetic Macular Edema (DME)

The safety and efficacy of EYLEA HD was assessed in a randomized, multi-center, double-masked, active-controlled study (PHOTON) in patients with DME involving the center of the macula. A total of 658 patients were treated and analyzed for efficacy (491 with EYLEA HD). Patients were randomly assigned in a 2:1:1 ratio to 1 of 3 treatment groups: 1) EYLEA HD administered every 12 weeks following 3 initial monthly doses (HDq12); 2) EYLEA HD administered every 16 weeks following 3 initial monthly doses (HDq16); 3) EYLEA 2 mg administered every 8 weeks (2q8) following 5 initial monthly doses. In the EYLEA HD groups, patients could be treated as frequently as every 8 weeks based on protocol-defined visual and anatomic criteria, starting at week 16. Patient ages ranged from 24 to 90 years with a mean of 62.3 years. A total of 44% of patients were previously treated for DME. At baseline, the overall mean visual acuity was 63 letters (range: 24–79 letters).

The primary efficacy endpoint was the change from baseline in BCVA at week 48 as measured by the ETDRS letter score. Both HDq12 and HDq16 treatments were shown to be non-inferior and clinically equivalent to 2q8 treatment with respect to the change in BCVA score at week 48 using the pre-specified non-inferiority margin of 4 letters. In patients completing week 48, the mean number of injections administered were 5.0 in the HDq16 group (n=155), 6.0 in the HDq12 group (n=298) and 7.9 in the EYLEA 2q8 group (n=156). Detailed results from the analysis of the PHOTON study are shown in Table 3 and Figure 9 below.

### Table 3: Efficacy Outcomes (Full Analysis Set) in PHOTON Study

<table>
<thead>
<tr>
<th>Efficacy Outcomes</th>
<th>EYLEA HDq12</th>
<th>EYLEA HDq16</th>
<th>EYLEA 2q8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Analysis Set[^a]</td>
<td>N=328</td>
<td>N=163</td>
<td>N=167</td>
</tr>
<tr>
<td>Mean change in BCVA as measured by ETDRS letter score from baseline (SD) at week 48[^b]</td>
<td>8.8 (9.0)</td>
<td>7.9 (8.4)</td>
<td>9.2 (9.0)</td>
</tr>
<tr>
<td>LS mean (SE) change from baseline[^c]</td>
<td>8.1 (0.6)</td>
<td>7.2 (0.7)</td>
<td>8.7 (0.7)</td>
</tr>
<tr>
<td>Difference in LS mean (95% CI)</td>
<td>-0.6 (-2.3, 1.1)</td>
<td>-1.4 (-3.3, 0.4)</td>
<td></td>
</tr>
</tbody>
</table>

BCVA = Best Corrected Visual Acuity; ETDRS = Early Treatment Diabetic Retinopathy Study; SD = Standard Deviation; LS = Least Square; SE = Standard Error; CI = Confidence Interval; MMRM = Mixed Model for Repeated Measurements.

[^a]: FAS includes all randomized patients who received at least 1 dose of study medication.
[^b]: Observed values at week 48: n=277 for HDq12; n=149 for HDq16; n=150 for 2q8.
[^c]: Estimate based on the MMRM model, was computed for the differences of HDq12 minus 2q8 and HDq16 minus 2q8, respectively with two-sided 95% CIs.

Efficacy results in all subgroups (e.g., age, gender, geographic region, ethnicity, race, baseline, BCVA, baseline CRT and prior DME treatment) were consistent with those in the overall population.

Figure 9: Mean Change from Baseline in BCVA as measured by ETDRS Letter Score by Visits through Week 48 (Observed Cases)

### 14.3 Diabetic Retinopathy (DR)

Efficacy and safety data of EYLEA HD in diabetic retinopathy (DR) are derived from the PHOTON study.

In the PHOTON study, a key efficacy outcome was the change in the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (ETDRS-DRSS). Each EYLEA HD group was compared to the 2q8 group using a NI margin of 10%.

The ETDRS-DRSS score was assessed at baseline and approximately every 3 months thereafter for the duration of the study [see Clinical Studies (14.2)]. Baseline ETDRS-DRSS scores were generally balanced across treatment groups.

Results from the analysis of ETDRS-DRSS scores at week 48 in the PHOTON study are shown in Table 4 below:

### Table 4: Proportion of Patients Who Achieved a ≥2-step Improvement from Baseline in the ETDRS-DRSS Score at Week 48 (Full Analysis Set) in PHOTON

<table>
<thead>
<tr>
<th>Efficacy Outcomes</th>
<th>EYLEA HDq12</th>
<th>EYLEA HDq16</th>
<th>EYLEA 2q8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Analysis Set[^a]</td>
<td>N=328</td>
<td>N=163</td>
<td>N=167</td>
</tr>
<tr>
<td>Proportion of patients with a ≥2-step improvement on ETDRS-DRSS from baseline (%)[^b]</td>
<td>29%</td>
<td>20%</td>
<td>27%</td>
</tr>
<tr>
<td>Difference (%) (95% CI)</td>
<td>2% (-6.6, 10.6)</td>
<td>-8% (-16.9, 1.8)</td>
<td></td>
</tr>
</tbody>
</table>

[^a]: FAS includes all randomized patients who received at least 1 dose of study medication.
[^b]: Last observation carried forward.
[^c]: Difference with confidence interval (CI) was calculated using Mantel-Haenszel weighting scheme.

Missing or non-gradable post-baseline ETDRS-DRSS values were imputed using the last gradable ETDRS-DRSS values. Patients were considered as non-responders if all post-baseline measurements were missing or non-gradable. Missing or ungradable baseline was not included in the denominator.

The EYLEA HDq16 did not meet the non-inferiority criteria for the proportion of patients with a ≥2-step improvement on ETDRS-DRSS and is not considered clinically equivalent to EYLEA administered every 8 weeks.

Results of the subgroups (e.g., age, gender, race, ethnicity, baseline BCVA and prior DME treatment) on the proportion of patients who achieved a ≥2-step improvement on the ETDRS-DRSS from baseline to week 48 were, in general, consistent with those in the overall population.

### 16 HOW SUPPLIED/STORAGE AND HANDLING

#### 16.1 How Supplied

EYLEA HD (aflibercept) is a clear to slightly opalescent, colorless to pale yellow solution supplied in the following presentations [see Dosage and Administration (2.9) and (2.10)]. Each vial is for single eye use only. Discard unused portion.
### 16.2 Storage and Handling
Refrigerate EYLEA HD at 2°C to 8°C (36°F to 46°F). Do not freeze. Do not use beyond the date stamped on the carton and container label. Store in the original carton until time of use to protect from light.

### 17 PATIENT COUNSELING INFORMATION
In the days following EYLEA HD administration, patients are at risk of developing endophthalmitis or retinal detachment. If the eye becomes red, sensitive to light, painful, or develops a change in vision, advise patients and/or caregivers to seek immediate care from an ophthalmologist [see Warnings and Precautions (5.1)].

Patients may experience temporary visual disturbances after an intravitreal injection with EYLEA HD and the associated eye examinations [see Adverse Reactions (6)]. Advise patients not to drive or use machinery until visual function has recovered sufficiently.

---

**REGENERON**

Manufactured by:
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
U.S. License Number 1760


EYLEA is a registered trademark of Regeneron Pharmaceuticals, Inc.
©2023, Regeneron Pharmaceuticals, Inc.
All rights reserved.
Date: August 2023
EHD.23.06.0027